Vir Biotechnology, Inc. (NASDAQ:VIR) Director George A. Scangos Sells 10,964 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) Director George A. Scangos sold 10,964 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total value of $107,556.84. Following the completion of the transaction, the director now owns 708,295 shares in the company, valued at $6,948,373.95. This represents a 1.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Vir Biotechnology Trading Down 0.5 %

Shares of NASDAQ VIR opened at $9.80 on Friday. Vir Biotechnology, Inc. has a 12-month low of $6.56 and a 12-month high of $14.45. The business’s fifty day simple moving average is $9.26 and its 200-day simple moving average is $8.48.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a report on Friday, January 31st. JPMorgan Chase & Co. upped their price objective on Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a report on Thursday, January 9th. Leerink Partners upped their price target on Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Needham & Company LLC restated a “buy” rating and set a $19.00 price target on shares of Vir Biotechnology in a research note on Wednesday, November 20th. Finally, Barclays decreased their price target on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.83.

Institutional Trading of Vir Biotechnology

Hedge funds have recently modified their holdings of the stock. Blue Trust Inc. raised its stake in shares of Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after acquiring an additional 2,351 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vir Biotechnology in the fourth quarter valued at $42,000. nVerses Capital LLC acquired a new stake in shares of Vir Biotechnology in the third quarter valued at $56,000. SBI Securities Co. Ltd. acquired a new stake in shares of Vir Biotechnology in the fourth quarter valued at $60,000. Finally, PNC Financial Services Group Inc. increased its holdings in Vir Biotechnology by 31.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock valued at $61,000 after buying an additional 1,999 shares during the last quarter. 65.32% of the stock is currently owned by institutional investors and hedge funds.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).